SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Inventories
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Inventories of $411.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $306.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $105.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $4.18M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $12.94M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2025 was $7.50M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2024 was -$15.81M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2023 was -$6.11M, a 134.21% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2022 was $17.86M, a 22.48% increase from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 6 month as first filed | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $411.00K 10-Q · filed 2026-08-03 | $4.59M derived: sum of 3 quarters · filed 2026-08-03 | $17.53M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | $105.00K 10-Q · filed 2026-05-05 | $4.29M derived: sum of 2 quarters · filed 2026-05-05 | $17.23M derived: sum of 3 quarters · filed 2026-05-05 | $12.34M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $17.12M derived: sum of 2 quarters · filed 2026-03-02 | $12.23M derived: sum of 3 quarters · filed 2026-08-03 | $7.50M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $12.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.05M derived: sum of 2 quarters · filed 2026-08-03 | $3.32M 10-Q · filed 2025-11-06 | $135.00K derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | -$4.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$9.62M 10-Q · filed 2026-08-03 | -$12.80M derived: sum of 3 quarters · filed 2026-08-03 | -$17.41M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | -$4.73M 10-Q · filed 2026-05-05 | -$7.92M derived: sum of 2 quarters · filed 2026-05-05 | -$12.52M derived: sum of 3 quarters · filed 2026-05-05 | -$18.55M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | -$3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$7.79M derived: sum of 2 quarters · filed 2026-03-02 | -$13.82M derived: sum of 3 quarters · filed 2026-03-02 | -$15.81M 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$10.63M derived: sum of 2 quarters · filed 2025-11-06 | -$12.62M 10-Q · filed 2025-11-06 | -$17.65M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-06-30 | -$6.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$8.02M 10-Q · filed 2025-08-05 | -$13.04M derived: sum of 3 quarters · filed 2026-03-02 | -$19.95M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-03-31 | -$1.99M 10-Q · filed 2025-05-06 | -$7.02M derived: sum of 2 quarters · filed 2026-03-02 | -$13.93M derived: sum of 3 quarters · filed 2026-03-02 | -$9.95M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2023-12-31 | -$5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$11.94M derived: sum of 2 quarters · filed 2026-03-02 | -$7.96M derived: sum of 3 quarters · filed 2026-03-02 | -$6.11M 10-K · filed 2026-03-02 | |
| 2023-09-30 | -$6.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$2.93M derived: sum of 2 quarters · filed 2024-11-04 | -$1.08M 10-Q · filed 2024-11-04 | $10.47M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $5.83M 10-Q · filed 2024-08-06 | $17.38M derived: sum of 3 quarters · filed 2025-02-25 | $25.53M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | $1.85M 10-Q · filed 2024-05-08 | $13.40M derived: sum of 2 quarters · filed 2025-02-25 | $21.55M derived: sum of 3 quarters · filed 2025-02-25 | $17.24M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | $11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $19.70M derived: sum of 2 quarters · filed 2025-02-25 | $15.39M derived: sum of 3 quarters · filed 2025-02-25 | $17.86M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $8.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $3.84M derived: sum of 2 quarters · filed 2023-11-08 | $6.30M 10-Q · filed 2023-11-08 | $11.55M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | -$4.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.84M 10-Q · filed 2023-08-08 | $3.41M derived: sum of 3 quarters · filed 2023-08-08 | $4.79M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $2.47M 10-Q · filed 2023-05-09 | $7.72M derived: sum of 2 quarters · filed 2023-05-09 | $9.10M derived: sum of 3 quarters · filed 2023-05-09 | $16.00M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $6.63M derived: sum of 2 quarters · filed 2023-03-09 | $13.53M derived: sum of 3 quarters · filed 2023-03-09 | $14.58M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $8.28M derived: sum of 2 quarters · filed 2022-11-09 | $9.33M 10-Q · filed 2022-11-09 | $14.02M derived: sum of 4 quarters · filed 2023-03-09 | |
| 2021-06-30 | $6.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $7.95M 10-Q · filed 2022-08-08 | $12.64M derived: sum of 3 quarters · filed 2023-03-09 | $20.03M derived: sum of 4 quarters · filed 2023-03-09 | |
| 2021-03-31 | $1.05M 10-Q · filed 2022-05-12 | $5.74M derived: sum of 2 quarters · filed 2023-03-09 | $13.13M derived: sum of 3 quarters · filed 2023-03-09 | $13.38M derived: sum of 4 quarters · filed 2023-03-09 | |
| 2020-12-31 | $4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $12.08M derived: sum of 2 quarters · filed 2023-03-09 | $12.33M derived: sum of 3 quarters · filed 2023-03-09 | $10.12M 10-K · filed 2023-03-09 | |
| 2020-09-30 | $7.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $7.65M derived: sum of 2 quarters · filed 2021-11-05 | $5.44M 10-Q · filed 2021-11-05 | $6.56M derived: sum of 4 quarters · filed 2022-04-13 | |
| 2020-06-30 | $255.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$1.96M 10-Q · filed 2021-08-06 | -$1.69M 10-Q · filed 2020-08-17 | -$831.00K derived: sum of 3 quarters · filed 2022-04-13 | -$1.35M derived: sum of 4 quarters · filed 2022-04-13 |
| 2020-03-31 | -$2.21M 10-Q · filed 2021-05-07 | -$1.09M derived: sum of 2 quarters · filed 2022-04-13 | -$1.61M derived: sum of 3 quarters · filed 2022-04-13 | -$2.10M derived: sum of 4 quarters · filed 2022-04-13 | |
| 2019-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-13 | $604.00K derived: sum of 2 quarters · filed 2022-04-13 | $110.00K derived: sum of 3 quarters · filed 2022-04-13 | $969.00K 10-K · filed 2022-04-13 | |
| 2019-09-30 | -$520.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$1.01M derived: sum of 2 quarters · filed 2020-11-06 | -$155.00K 10-Q · filed 2020-11-06 | $2.22M derived: sum of 4 quarters · filed 2021-03-08 | |
| 2019-06-30 | -$494.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $365.00K 10-Q · filed 2020-08-17 | $2.74M derived: sum of 3 quarters · filed 2021-03-08 | $5.34M derived: sum of 4 quarters · filed 2021-03-08 | |
| 2019-03-31 | $859.00K 10-Q · filed 2020-05-15 | $3.24M derived: sum of 2 quarters · filed 2021-03-08 | $5.84M derived: sum of 3 quarters · filed 2021-03-08 | $7.44M derived: sum of 4 quarters · filed 2021-03-08 | |
| 2018-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $4.98M derived: sum of 2 quarters · filed 2021-03-08 | $6.58M derived: sum of 3 quarters · filed 2021-03-08 | $9.36M 10-K · filed 2021-03-08 | |
| 2018-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $4.21M derived: sum of 2 quarters · filed 2019-11-08 | $6.98M 10-Q · filed 2019-11-08 | $8.33M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $4.38M 10-Q · filed 2019-08-09 | $5.73M derived: sum of 3 quarters · filed 2020-02-28 | $4.06M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-03-31 | $2.77M 10-Q · filed 2019-05-10 | $4.13M derived: sum of 2 quarters · filed 2020-02-28 | $2.45M derived: sum of 3 quarters · filed 2020-02-28 | -$92.00K derived: sum of 4 quarters · filed 2020-02-28 | |
| 2017-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$319.00K derived: sum of 2 quarters · filed 2020-02-28 | -$2.86M derived: sum of 3 quarters · filed 2020-02-28 | -$497.00K 10-K · filed 2020-02-28 | |
| 2017-09-30 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$4.22M derived: sum of 2 quarters · filed 2018-11-09 | -$1.85M 10-Q · filed 2018-11-09 | -$2.51M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | -$2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$178.00K 10-Q · filed 2018-08-09 | -$830.00K derived: sum of 3 quarters · filed 2019-03-01 | $250.00K derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | $2.37M 10-Q · filed 2018-05-10 | $1.71M derived: sum of 2 quarters · filed 2019-03-01 | $2.79M derived: sum of 3 quarters · filed 2019-03-01 | $6.12M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2016-12-31 | -$652.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $428.00K derived: sum of 2 quarters · filed 2019-03-01 | $3.76M derived: sum of 3 quarters · filed 2019-03-01 | $4.21M 10-K · filed 2019-03-01 | |
| 2016-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $4.41M derived: sum of 2 quarters · filed 2017-11-09 | $4.87M 10-Q · filed 2017-11-09 | $2.71M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | $3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $3.79M 10-Q · filed 2017-08-03 | $1.63M derived: sum of 3 quarters · filed 2018-03-01 | $2.78M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | $457.00K 10-Q · filed 2017-05-09 | -$1.70M derived: sum of 2 quarters · filed 2018-03-01 | -$548.00K derived: sum of 3 quarters · filed 2018-03-01 | -$658.00K derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | -$2.15M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | -$1.00M derived: sum of 2 quarters · filed 2018-03-01 | -$1.11M derived: sum of 3 quarters · filed 2018-03-01 | -$854.00K 10-K · filed 2018-03-01 | |
| 2015-09-30 | $1.15M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-01-20 | $1.04M derived: sum of 2 quarters · filed 2017-01-23 | $1.30M 10-Q/A · filed 2017-01-20 | $3.60M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | -$110.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-01-23 | $151.00K 10-Q/A · filed 2017-01-23 | $2.45M derived: sum of 3 quarters · filed 2017-03-16 | $3.49M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-03-31 | $261.00K 10-Q/A · filed 2017-01-20 | $2.56M derived: sum of 2 quarters · filed 2017-03-16 | $3.60M derived: sum of 3 quarters · filed 2017-03-16 | $5.75M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2014-12-31 | $2.30M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $3.34M derived: sum of 2 quarters · filed 2017-03-16 | $5.48M derived: sum of 3 quarters · filed 2017-03-16 | $6.29M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $1.04M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $3.19M derived: sum of 2 quarters · filed 2017-01-20 | $3.99M 10-Q/A · filed 2017-01-20 | $5.96M derived: sum of 4 quarters · filed 2017-01-20 | |
| 2014-06-30 | $2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $2.95M 10-Q · filed 2015-08-07 | $4.91M derived: sum of 3 quarters · filed 2017-01-20 | $5.79M derived: sum of 4 quarters · filed 2017-01-20 | |
| 2014-03-31 | $805.00K 10-Q · filed 2015-05-06 | $2.77M derived: sum of 2 quarters · filed 2017-01-20 | $3.64M derived: sum of 3 quarters · filed 2017-01-20 | $4.84M derived: sum of 4 quarters · filed 2017-01-20 | |
| 2013-12-31 | $1.96M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $2.84M derived: sum of 2 quarters · filed 2017-01-20 | $4.04M derived: sum of 3 quarters · filed 2017-01-20 | $6.00M 10-K/A · filed 2017-01-20 | |
| 2013-09-30 | $873.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $2.08M derived: sum of 2 quarters · filed 2014-11-12 | $4.04M 10-Q · filed 2014-11-12 | $5.16M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $3.16M 10-Q · filed 2014-08-12 | $4.29M derived: sum of 3 quarters · filed 2015-03-12 | ||
| 2013-03-31 | $1.96M 10-Q · filed 2014-05-13 | $3.09M derived: sum of 2 quarters · filed 2015-03-12 | |||
| 2012-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $1.15M 10-K · filed 2015-03-12 | |||
| 2012-09-30 | $26.00K 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |